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Objective: The objectives were to investigate the in vivo effects of treatment with rebamipide on pain
severity and cartilage degeneration in an experimental model of rat osteoarthritis (OA) and to explore its
mode of action.
Materials and methods: OA was induced in rats by intra-articular injection of monosodium iodoacetate
(MIA). Oral administration of rebamipide was initiated on the day of MIA injection, 3 or 7 days after. Limb
nociception was assessed by measuring the paw withdrawal latency and threshold. We analyzed the
samples macroscopically and histomorphologically, and used immunohistochemistry to investigate the
expression of matrix metalloproteinase-13 (MMP-13), interleukin-1b (IL-1b), hypoxia-inducible factor-2a
(HIF-2a), inducible nitric oxide synthase (iNOS), and nitrotyrosine in knee joints. Real-time quantitative
reverse transcriptionepolymerase chain reaction was used to quantify the mRNA for catabolic and
anticatabolic factors in human OA chondrocytes.
Results: Rebamipide showed an antinociceptive property and attenuated cartilage degeneration. Reba-
mipide reduced the expression of MMP-13, IL-1b, HIF-2a, iNOS, and nitrotyrosine in OA cartilage in
a dose-dependent manner. Nitrotyrosine expression in the subchondral bone region was decreased in
the rebamipide-treated joints. mRNA expression of MMP-1, -3, and -13, and ADAMTS5 was attenuated in
IL-1b-stimulated human OA chondrocytes. By contrast, rebamipide induced the mRNA expression of
tissue inhibitor of metalloproteinase-1 and -3.
Conclusion: The results show the inhibitory effects of rebamipide on pain production and cartilage degen-
eration in experimentally induced OA. The suppression of oxidative damage and the restoration of extra-
cellular matrix homeostasis of articular chondrocyte suggest that rebamipide is a potential therapeutic
strategy for OA.
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Osteoarthritis (OA) is a degenerative joint disease characterized
by the progressive loss of cartilage, changes in subchondral bone,
and chronic pain. The lack of anabolic factors such as insulin-like
growth factor-1 and bone morphogenic proteins and increased
inﬂuence of catabolic factors such as collagenases and aggrecanases
lead to the pathological degradation of the cartilage extracellular
matrix (ECM), the hallmark of OA pathology.
The development and progression of OA are now believed to
involve inﬂammation1. Proinﬂammatory cytokines and chemokines
are critical mediators of the disturbed homeostasis in the OA
cartilage matrix2e6. Interleukin-1 (IL-1)b among them playsbehalf of Osteoarthritis Research Society International. All rights reserved.
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components by inhibiting anabolic activities7 and increasing cata-
bolic activities8 in chondrocytes.
Chronic oxidative stress is thought to underlie the pathophys-
iology of many autoimmune diseases, including rheumatoid
arthritis (RA), Sjögren’s syndrome, and Behçet’s disease9e11. Many
studies have shown that, like RA, OA is associated with oxidative
stress, although to a lesser extent12,13. Excess production of
oxidants such as nitric oxide (NO) has been linked with apoptosis
of cartilage chondrocytes both in vitro and in vivo14,15. Although
the relative contribution of chondrocyte apoptosis to the OA
pathogenesis is debated, an important role of chondrocyte
apoptosis in OA has been demonstrated16,17. The observations that
human articular chondrocytes actively produce reactive oxygen
species (ROS)18 and that higher intracellular ROS are detected in
chondrocytes from the articular cartilage in old rats than in young
adult rats19 may explain why age is one of the strongest risk
factors for OA.
Rebamipide is a gastroprotective agent used for the treatment of
gastritis and gastric ulcer. Substantial research shows that reba-
mipide acts as an oxygen radical scavenger20 and exhibits an anti-
inﬂammatory property21. Recent studies veriﬁed that rebamipide
reduces inﬂammation in an animal model of Behçet’s disease22 and
decreases apoptosis in the salivary and lacrimal glands in a mouse
model of Sjögren’s syndrome23.
To our knowledge, the effect of rebamipide has not been
investigated in an animal model of OA or RA. Given the potential
important role of oxidative stress in OA pathogenesis and the
oxygen free radical-scavenging property of rebamipide, we inves-
tigated the effects of rebamipide on pain generation, cartilage
destruction, and various indicators of local oxidative damage and
inﬂammatory status in a monosodium iodoacetate (MIA)-induced
OA rat model, which mimics the pain and biochemical/structural
changes associated with OA24.
Materials and methods
Animals
Male Wistar rats weighing 140e230 g (6 weeks of age) at the
start of the experiment were purchased from Central Lab. Animal
Inc. (Seoul, South Korea). The animals were housed two per cage in
a room with controlled temperature conditions (21e22C) with
controlled lighting (12-h light/12-h dark cycle) and had access to
sterile food and water. To assure the efﬁcacy of rebamipide in an OA
model, the mice were randomized to four groups of 10 mice each.
And, to conﬁrm the therapeutic potential of rebamipide in an early
or established OA model, twenty-four mice were randomized into
four groups of six mice each. All animal procedures were approved
by the Animal Research Ethics Committee at the Catholic University
of Korea.
Induction of OA in the rat and treatment with rebamipide
The animals were randomized and assigned to treatment groups
before the study began. After anesthetization with isoﬂurane, rats
were injected with 50 ml containing 3 mg of MIA (Sigma) using
a 26.5-G needle inserted through the patellar ligament into the
intra-articular space of the right knee. Control rats were injected
with an equivalent volume of saline. Rebamipide was kindly
provided by Hanlim Pharmaceutical Company (Seoul, Korea).
Rebamipide dissolved in 10% dimethyl sulfoxide (DMSO) was
administered orally every day. The vehicle-treated animals were
given an equivalent volume of 10% DMSO solution. The doses of
rebamipide were 0.3, 3, and 10 mg/kg.Assessment of pain behavior
The MIA-treated rats were randomized to each experimental
group. Mechanical sensitivity was assessed using a dynamic plantar
esthesiometer (Ugo Basile), an automated version of the von Frey
hair assessment procedure, before the MIA injection (Day 0) and on
the given day after MIA injection. The rats were placed on a metal
mesh surface in an acrylic chamber in a temperature-controlled
room (21e22C) and allowed to rest for 15 min before the testing
began. The touch stimulator unit was oriented under the animal. An
adjustable angled mirror was used to place the stimulating
microﬁlament (0.5-mm diameter) below the plantar surface of the
hind paw. When the instrument was activated, a ﬁne plastic
monoﬁlament advanced at a constant speed and touched the paw
in the proximal metatarsal region. The ﬁlament exerted a gradually
increasing force on the plantar surface, starting below the
threshold of detection and increasing until the stimulus became
painful and the rat removed its paw. The force required to elicit
a paw withdrawal reﬂex was recorded automatically and measured
in g. A maximum force of 50 g and a ramp speed of 20 s were used
for all esthesiometry tests. Pain behavioral tests of mechanical
hyperalgesia were conducted right before the rebamipide
administration.
Histological and immunohistochemical analyses
Histological changes were assessed to conﬁrm the effect of
rebamipide on cartilage degeneration in the knee joints of OA rats.
The animals were perfused via the ascending aortawith 10% neutral
buffered formalin (pH 7.4). The knee joints, including the patella
and joint capsule, were resected and kept in the same ﬁxative for an
additional 48 h at 4C. The ﬁxed specimens were decalciﬁed with
5% formic acid decalciﬁer for 6 days at 4C. After decalciﬁcation, the
specimens were embedded in parafﬁn. Standardized 7-mm serial
sections were obtained at the medial and lateral midcondylar level
in the sagittal plane and were stained with hematoxylin and eosin
(HE), Safranin Oefast green, and toluidine blue to enable evaluation
of proteoglycan content. Slides for immunohistochemistry were
deparafﬁnized and rehydrated using a graded ethanol series. The
sections were depleted of endogenous peroxidase activity by add-
ing methanolic H2O2 and then blocked with normal goat serum for
30 min. The samples were incubated overnight at 4C with anti-
bodies to nitrotyrosine (Santa Cruz), IL-1b (Santa Cruz), matrix
metalloproteinase-13 (MMP-13) (Abcam), or hypoxia-inducible
factor-2a (HIF-2a) (Abcam). The samples were then incubated
with the respective secondary antibodies, biotinylated anti-mouse
IgG or rabbit IgG, for 20 min, conjugated to a streptavidine
peroxidase complex (Vector Laboratories) for 1 h, and ﬁnally with
3,30-diaminobenzidine (Dako). The sections were counterstained
with Mayer’s hematoxylin and photographed using an Olympus
photomicroscope (Japan).
A modiﬁed Mankin’s histological score25 (original score
proposed byMankin et al. 26) was used to score histological injuries
of the articular cartilage as follows. The structure was scored on
a scale of 0e6, where 0 ¼ normal; 1 ¼ irregular surface, including
ﬁssures into the radial layer; 2 ¼ pannus; 3¼ absence of superﬁcial
cartilage layers (6); 4 ¼ slight disorganization (cellular row
absent, some small superﬁcial clusters); 5 ¼ ﬁssure into the calci-
ﬁed cartilage layer; and 6 ¼ disorganization (chaotic structure,
clusters, and osteoclasts activity). Cellular abnormalities were
scored on a scale of 0e3, where 0 ¼ normal; 1 ¼ hypercellularity,
including small superﬁcial clusters; 2 ¼ clusters; and
3¼ hypocellularity. The matrix staining was scored on a scale of 0e
4, where 0 ¼ normal/slight reduction in staining; 1 ¼ staining
reduced in the radial layer; 2 ¼ staining reduced in the
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matrix; and 4¼ staining absent. Joint spacewidth was estimated by
sum of the nearest distance of medial and lateral tibiofemoral
joints.
Microscopic assessment of OA joints
The tibia and femur bones were separated, and all excess soft
tissue was removed by careful dissection under a dissecting
microscope. The articular surface of each specimenwas rinsed with
phosphate-buffered saline (PBS). The cartilage surfaces of the
femoral condyle and the tibial plateau were examined on
a microscope.
Primary culture and treatment of OA chondrocytes
The study was approved by the local ethics committee, and
informed consent was obtained from all patients with OA, who
fulﬁlled the American College of Rheumatology criteria for this
disease27. Cartilage samples were washed in calcium- and
magnesium-free PBS and ﬁnely ground. Chondrocytes were ob-
tained by digesting the articular cartilage with 0.2% pronase
(Sigma) for 1 h, followed by digestion with 0.2% Clostridia colla-
genase (Sigma) for 3 h at 37C in high-glucose Dulbecco’s modiﬁed
Eagle medium (DMEM; Life Technologies) containing an
antibioticeantimycotic solution (100 U/ml penicillin, 100 mg/ml
streptomycin, and 0.25 mg/ml amphotericin B; Life Technologies).
Undigested cartilage was removed with a 70-mg nylon mesh (Cell
Strainer; Falcon), and the chondrocytes were collected by centri-
fugation, washed twice, and resuspended in DMEM with 10% fetal
bovine serum (FBS; Life Technologies). Finally, the cells were plated
in 100-mm tissue culture dishes for expansion at 37C in a 5% CO2
humidiﬁed atmosphere for 10 days (Shel Lab). The medium of the
suspension culture was changed every 2e3 days. In all experi-
ments, chondrocytes were cultured under FBS-free DMEM condi-
tions (5%, v/v) and were used in monolayers at conﬂuence. Cells
(1105 cells/well) were placed in 24-well tissue culture plates, and
the mediumwas replaced with serum-free DMEM on the next day.
Twenty-four hours later, the cells were pretreated with rebamipide
for 2 h and then stimulatedwith or without recombinant human IL-
1b (20 ng/ml; R&D Systems) for 48 h. The viability of human
chondrocytes was estimated by measuring cell metabolic activity
using the cell counting kit (CCK)-8.
Reverse transcription reaction and real-time polymerase chain
reaction (PCR)
Total RNA was isolated from human chondrocytes using the
TRIzol method (Invitrogen). The complimentary DNA (cDNA) was
prepared by reverse transcription of the single-stranded RNA
according to the manufacturer’s directions included in the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The
levels of mRNA expression were estimated using real-time quan-
titative PCR with LightCycler FastStart DNA Master SYBR green I
(Takara), according to the manufacturer’s instructions. The primer
pairs used in these reactions were as follows: for control human b-
actin, forward 50-GGA CTT CGA GCA AGA GAT GG-30, reverse 50-TGT
GTT GGC GTA CAG GTC TTT G-30; for human tissue inhibitor of
metalloproteinase (TIMP)-1, forward 50-AAT TCC GAC CTC GTC ATC
AG-30, reverse 50-TGC AGT TTT CCA GCA ATG AG-30; for human
TIMP-3, forward 50-CTG ACA GGT CGC GTC TAT GA-30, reverse 50-
GGC GTA GTG TTT CTG GT-30; for human MMP-1, forward 50-GGG
AGA TCA TCG GGA CAA CTC-30, reverse 50-GGG CCT GGT TGA AAA
GCA T-30; for human MMP-3, forward 50-TGG CAT TCA GTC CCT CTA
TGG-30, reverse 50-AGG ACAA AGC AGG ATC ACA GTT-30; for humanMMP-13, forward 50-AAG GAG CAT GGC GAC TTC T-30, reverse 50-
TGG CCC AGG AGG AAA AGC-30; and for human ADAMTS5, forward
50-TAT GAC AAG TGC GGA GTA TG-30, reverse 50-TTC AGG GCT AAA
TAG GCA GT-30. The ampliﬁcation reactions, data acquisition, and
analysis were performed with the LightCycler Real-Time PCR
system (Roche Diagnostics), and the relative levels of gene
expression were normalized against b-actin.
Statistical analysis
The change of pain behavior is expressed as means  standard
error of themean (S.E.M.). Each value of histological assessments and
pain behaviors was represented as a dot plot. KruskaleWallis test
was used for anabolic and catabolic activities in human OA chon-
drocytes. One-way analysis of variance followed by Bonferroni’s
post-hoc test was used to compare pain and histological scores. To
assess the Gaussian distribution and the equality of variance,
ShapiroeWilk test and Levene test were used, respectively. The
program used for the statistical analysis was SPSS statistical soft-
ware package standard version 16.0 (SPSS Inc., Chicago, IL). P values
less than 0.05 (two-tailed) were considered signiﬁcant.
Results
The effect of rebamipide on pain and cartilage degeneration in an
OA animal model
Because pain is the predominant symptom of OA, we assessed
the nociceptive response and performed histological examination
7 days after MIA injection. The treatment of rebamipide was
initiated on the day of MIA injection. The previous pharmacoki-
netics study showed that peak plasma concentration of rebami-
pide was observed around 1 h after oral administration28. After
that, the serum concentration of the compound was decreased
constantly. Therefore, we conducted pain behavioral tests right
before the administration of rebamipide to avoid the peak
concentration of rebamipide. In the von Frey hair assessment test,
the paw withdrawal latency (PWL) and the paw withdrawal
threshold (PWT) were prolonged signiﬁcantly in the inﬂamed hind
paw of the rats given oral rebamipide (3 and 10 mg/kg) compared
with the placebo group (Fig. 1), demonstrating the antinociceptive
property of rebamipide in OA animals. On day 7 after intra-
articular injection of MIA, the treatment with rebamipide at
a dose of 0.3, 3, or 10 mg/kg once daily provided an in vivo
cartilage-protective effect that was seen macroscopically. The area
of eroded cartilage surface was reduced in the joints of
rebamipide-treated rats (Fig. 2).
Microscopic ﬁndings and modiﬁed Mankin scores in cartilage
To evaluate the chondroprotective effect of rebamipide, the
isolated knee joints from the ﬁve groups were analyzed micro-
scopically. In the control group, staining with HE, Safranin Oefast
green, and toluidine blue showed a smooth surface of the artic-
ular cartilage, normal cellularity, and intensive Safranin Oefast
green and toluidine blue staining. By contrast, the joints from
MIA-induced OA rats showed joint space narrowing and marked
depletion of proteoglycan. These histomorphological changes in the
cartilage were reduced in the rebamipide-treated OA animals. In
the MIA-induced OA rats treated with 10 mg/kg of rebamipide, the
cartilage thickness and the degree of proteoglycan content did not
differ from those of the control rats [Fig. 3(A)]. The overall modiﬁed
Mankin scores were signiﬁcantly lower in rebamipide-treated rats
with OA (3 or 10 mg/kg) than in untreated OA rats [Fig. 3(B)].
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Fig. 1. Effects of rebamipide on mechanical hyperalgesia in a model of MIA-induced OA in rats. Rats were injected with 3 mg of MIA in the right knee. Rebamipide was
administered orally every day for 7 days after MIA injection. Behavioral tests of mechanical hyperalgesia in MIA-injected rats treated with vehicle or rebamipide were evaluated
using a dynamic plantar esthesiometer on day 7 (n ¼ 10 on each day for each group). Compared with vehicle-treated OA rats, OA animals treated with rebamipide at a dose of 3 or
10 mg/kg showed a signiﬁcant prolongation in PWL (A) or PWT (B). The data are expressed as dot plots with mean (bar) for 10 animals per group. PWL and PWT were conducted
right before the administration of rebamipide. Signiﬁcant differences between vehicle- and rebamipide-treated groups: *P < 0.05 and **P < 0.01 compared with the vehicle-treated
OA group.
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the cartilage of rebamipide-treated OA rats
The number of chondrocytes stained positively for MMP-13
increased in the MIA-induced OA cartilage. The percentage of
MMP-13-positive chondrocytes was signiﬁcantly lower in the
rebamipide-treated group than in the vehicle-treated group. MMP-
13-positive chondrocytes were seen rarely in the rats treated with
rebamipide at a dose of 3 and 10 mg/kg [Fig. 4(A)]. The expression
of IL-1b, the main mediator of the induction of the synthesis of
MMP-13 in chondrocytes29, was lower in the articular cartilage of
rebamipide-treated animals [Fig. 4(B)]. HIF-2a also acts as a cata-
bolic regulator of cartilage destruction in the OA process30. As for
IL-1b and MMP-13, the percentage of chondrocytes staining posi-
tive for HIF-2a was also lower in the rebamipide-treated animals
[Fig. 4(C)].
Reduced expression of inducible nitric oxide synthase (iNOS) and
nitrotyrosine in cartilage and the subchondral bone region in OA
rats treated with rebamipide
To determine the degree of oxidative damage in the knee joints
of rebamipide-treated OA rats, immunohistochemistry was used to
assess the expression of iNOS and nitrotyrosine on day 7 after MIA
injection. The expression of iNOS and nitrotyrosine increased
markedly in the articular cartilage of MIA-injected joints [Fig. 5].
Because subchondral bone changes develop 7 days after intra-
articular injection of MIA31, we examined the change in oxida-
tive stress markers in the subchondral bone region. Nitrotyrosine
expression was signiﬁcantly greater in the subchondral bone
region in the MIA-injected joints than in those from the control
animals. The expression of iNOS and nitrotyrosine was also
detected in the inﬂamed synovium. As shown in Fig. 5, the
treatment with rebamipide reduced the proportion of iNOS-
positive chondrocytes in the superﬁcial cartilage and the levels
of nitrotyrosine expression in articular cartilage and in sub-
chondral bone.Therapeutic efﬁcacy of rebamipide in an early phase of OA animal
model
To determine the therapeutic effect of rebamipide in an early
phase of OA joints, rebamipide treatmentwas initiated on day 3 after
MIA injection. Signiﬁcant painwas developed on day 3 in our animal
model [Fig. 6(A) and (B)]. Although the thinning or loss of articular
cartilagewasnotevident, proteoglycancontentsweredepleted in the
MIA-injected OA joints at that point (data not shown). The anti-
nociceptive property of rebamipide had been sustained till 3 weeks
afterMIA injection at a dose of 3 or 10mg/kg. The knee joints isolated
from the rebamipide-treated OA rats (on day 21) showed less extent
of proteoglycan depletion and cartilage thinning, compared with
vehicle-treated group [Fig. 6(C)] (n ¼ 6 for each group).
Therapeutic efﬁcacy of rebamipide in an established OA model
To conﬁrm the therapeutic potential of rebamipide in an estab-
lished OA, the initiation time point of rebamipide administration
was delayed to day 7 after MIA injection. Signiﬁcant pain was
generated on day 7 [Fig. 7(A) and (B)]. The antinociceptive property
of rebamipide had been also identiﬁed in the established OAmodel
and has been sustained till 3 weeks afterMIA injection at a dose of 3
or 10mg/kg (n¼ 6 for each group). The knee joints isolated from the
rebamipide-treated OA rats (on day 21) showed chondroprotective
property of rebamipide and also demonstrated the attenuated
oxidative damage, compared with vehicle-treated group [Fig. 7(C)].
Taking the results into consideration, it may be conceivable that
rebamipide has therapeutic potential to delay disease progression
and also has the inhibitory effect on pain production in OA.
Effects of rebamipide on the gene expression of MMP-1, MMP-3,
MMP-13, ADAMTS5, TIMP-1, and TIMP-3 in human OA chondrocytes
We next investigated the possible role of rebamipide in modu-
lating the expression of catabolic and anticatabolic molecules in
human OA chondrocytes. Figure 8(A) shows that the gene
Fig. 2. Macroscopic photographs of the femoral and tibial articular cartilage after treatment with rebamipide in MIA-induced OA rats. Rats were injected with 3 mg of MIA in
the right knee. Rebamipide was administered orally every day for 7 days after MIA injection. The gross morphological changes of the femoral condyles and tibial plateau were
photographed using a digital camera to contrast the cartilage lesions. Seven days after intra-articular injection of MIA, extensive areas of cartilage loss and erosion were apparent in
the femoral condyles and tibial plateau, whereas the rebamipide-treated group showed less cartilage destruction.
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IL-1b and that this effect was reduced after the treatment with
1000 mM of rebamipide. The mRNA expression of ADAMTS5 in OA
chondrocytes was reduced signiﬁcantly after treatment with
200 mM of rebamipide and remained suppressed at higher
concentrations [Fig. 8(A)]. ThemRNAexpression of the anticatabolic
factors TIMP-1 and -3 was signiﬁcantly higher in cells cultured in
the presence of rebamipide (5000 mM) than in those culturedwithout rebamipide [Fig. 8(B)]. Cell viability determined by CCK-8
assay was not altered in the doses of our study (data not shown).
Discussion
We found that the oral administration of rebamipide attenuated
the pain severity and cartilage destruction, and reduced oxidative
stress in articular cartilage and the subchondral bone region in an
Fig. 3. Histological evaluation of joints after treatment with rebamipide in MIA-induced OA. Rats were injected with 3 mg of MIA in the right knee. Rebamipide was
administered orally every day for 7 days after MIA injection. (A) The knee joints from the OA rats treated with rebamipide or vehicle were stained with HE, Safranin Oefast green,
and toluidine blue. Extensive cartilage degradation, bone destruction, and ﬁbrosis are seen in the vehicle-treated group, whereas the treatment with rebamipide preserved the
articular space and prevented the depletion of proteoglycan. Rebamipide treatment preserved the cartilage structure and decreased the depth and the extent of cartilage damage.
(B) The joint lesions were graded on a scale of 0e13 using the modiﬁed Mankin scoring system, giving a combined score for cartilage structure, cellular abnormalities, and matrix
staining, and an overall Mankin score. Rebamipide prevented damage to the cartilage structure, reduced cellular abnormalities, and preserved matrix staining. The data are
expressed as dot plots with mean (bar) for 10 animals per group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the MIA-injected vehicle-treated group.
Fig. 4. Effects of rebamipide on the expression of MMP-13, IL-1b, and HIF-2a in OA joints. Rats were injected with 3 mg of MIA in the right knee. Rebamipide was administered
orally every day for 7 days after MIA injection. Immunohistochemical staining was used to identify the expression of MMP-13 (A), IL-1b (B), and HIF-2a (C) in the articular cartilage.
In the articular cartilage of MIA-injected rats, the expression of MMP-13, IL-1b, and HIF-2a increased, whereas treatment with rebamipide inhibited the expression of these
molecules. The data are expressed as dot plots with mean (bar) for ﬁve experiments per group. Original magniﬁcation 400.
S.-J. Moon et al. / Osteoarthritis and Cartilage 20 (2012) 1426e14381432animal model of OA. The chondroprotective property of rebamipide
was associated with reduced catabolism of articular cartilage
matrix. MMPs, ADAMTS5, and HIF-2awere implicated as mediators
of the effect of rebamipide as an anticatabolic regulator of cartilage
destruction in our animal model and in human OA chondrocytes.
Although cartilage degeneration is a basic issue in OA, it is not
the source of pain because cartilage does not contain nerves. The
etiology of pain in OA has not been elucidated fully. However, it has
been suggested that afferent innervation of the subchondral bone,
periosteum, synovium, ligaments, and joint capsule could be
sources of nociceptive stimuli32. The generation of joint pain results
from activation of primary afferent nerve ﬁbers33. Among various
subpopulations, medium- to large-diameter neurons that express
calcitonin gene-related peptide (CGRP) are thought to be involved
in peripheral and central sensitization of joint afferent neurons in
inﬂammatory arthritis34. In patients with hip OA, the innervations
density of CGRP-immunoreactive nerve ﬁbers was increased in
patients with painful hip OA35. In these patients, those who did not
experience pain lacked CGRP-containing afferents. The MIA-
induced OA animal model is a well-characterized model of pain-
ful joint degeneration. In animals with MIA-induced OA, CGRP isalso augmented in the dorsal root ganglion, where the cell bodies of
joint afferent neurons are located36.
In this study, the expression of IL-1b, iNOS, and nitrotyrosine
was also signiﬁcantly reduced after treatment with rebamipide.
These results suggest that the attenuation of articular cartilage
injury in the rebamipide-treated groups was associated with
reduced oxidative stress and decreased inﬂammation-related
events. A recent study showed that rebamipide works as an anti-
inﬂammatory agent in both acute and chronic inﬂammation and
has an inhibitory effect on proinﬂammatory cytokines37.
The pathophysiology responsible for OA development and
progression is complex and poorly understood. The current concept
of OA has changed to include an active biological process of matrix
degradation mediated by cells within the joints38, reﬂecting a shift
in focus on the catabolic mechanisms in ECM leading to OA.
MMPs can degrade all components of the ECM, and their over-
expression and activation contribute to many pathologies,
including joint destruction in OA. Proinﬂammatory cytokines
upregulate MMP expression in a variety of tissues and cell types,
including articular chondrocytes39. IL-1b, one of the most active
factors involved in OA, diminishes the expression of type 2 collagen
S.-J. Moon et al. / Osteoarthritis and Cartilage 20 (2012) 1426e1438 1433and aggrecan, and increases the expression of MMP-1, -3, and -1340.
MMP-13 is one of the key enzymes implicated in the pathogenesis
of cartilage destruction. MMP-13 is not found in normal adult
tissues but is expressed in the joints and articular cartilage of OA
patients41. It was suggested that inhibition of MMP-13 expression
may provide beneﬁcial chondroprotective effects in OA42. TIMPs are
endogenous regulators of MMP activity and may represent an
anticatabolic strategy in OA. In particular, the therapeutic potentialFig. 5. Attenuated oxidative damage represented by iNOS and nitrotyrosine expression
knee. Rebamipide was administered orally every day for 7 days after MIA injection. Immuno
the joint tissue. iNOS and nitrotyrosine expression in OA chondrocytes increased in articular
data are expressed as dot plots with mean (bar) for ﬁve experiments per group. Original mof TIMP-3 has been highlighted. TIMP-3 deﬁciency causes a process
of cartilage degradation similar to the changes seen in patients with
OA43. Interestingly, TIMP-3 is a potent inhibitor of ADAMTS544, also
known as aggrecanase-2, the main enzyme responsible for aggre-
can degradation with ADAMTS4, and the inhibition of ADAMTS5
represents an important target in OA45. Our results also showed
that the mRNA expression of MMP-1, -3, and -13, and ADAMTS5 in
human OA chondrocytes decreased signiﬁcantly after treatmentin rebamipide-treated rats with OA. Rats were injected with 3 mg of MIA in the right
histochemical staining was used to identify the expression of iNOS and nitrotyrosine in
cartilage of MIA-injected rats but was reduced in rebamipide-treated OA animals. The
agniﬁcation 400.
S.-J. Moon et al. / Osteoarthritis and Cartilage 20 (2012) 1426e14381434with rebamipide, whereas the expression of TIMP-1 and -3
increased signiﬁcantly after treatment with rebamipide. Our results
suggest that rebamipide has potential in the treatment of OA.
Continuous oxidative stress to cells and matrix is one major
mechanism contributing to OA pathogenesis46. Elevated produc-
tion of ROS in combination with depletion of antioxidants is
implicated in the progression of disease. Such imbalance between
oxidants and antioxidants is referred to as oxidative stress. Extra-
cellular superoxide dismutase (EC-SOD), a scavenger of ROS,
decreases in human OA cartilage47, and increased production of NO
is thought to lead to human chondrocyte apoptosis thoroughFig. 6. Therapeutic efﬁcacy of rebamipide in an early phase of OA model. Rats were injec
from 3 days after MIA injection. Behavioral tests (PWL and PWT) showed that signiﬁcant deg
an antinociceptive property in vivo (A and B). Articular cartilages isolated from the rebam
a lesser extent, compared with vehicle-treated OA joints (C). PWL and PWT were conducted
(error bar) for six animals per group at each time point.mitochondrial dysfunction48. Because of the involvement of
increased apoptosis of chondrocytes in OA pathogenesis, ROS is
considered a potential treatment target.
Subchondral bone, which is often neglected in OA research, also
appears to be an important tissue49. It is not clear whether changes
within subchondral bone precede changes in the articular cartilage
or whether these tissue changes are secondary adaptation
processes after changes in the overlying articular cartilage. At
minimum, the changes in the subchondral bone in moderate to
advanced lesions represent one tissue that is responsible for joint
pain50. Subchondral sclerosis is implicated in the pain generation inted with 3 mg of MIA in the right knee. Rebamipide was administered orally every day
ree of pain was developed on day 3 and rebamipide at a dose of 3 or 10 mg/kg provided
ipide-treated OA rats (on day 21) showed proteoglycan loss and cartilage thinning to
right before the administration of rebamipide. The data are expressed as mean  S.E.M.
S.-J. Moon et al. / Osteoarthritis and Cartilage 20 (2012) 1426e1438 1435OA, and the treatment with an NO donor compound increases
subchondral sclerosis, suggesting a role for NO in the pain-
generation process in OA51. Therefore, oxidative stress may be an
attractive treatment target to relieve the pain of OA. Based on the
functional relevance of pain generation in arthritis, our results
showing that administration of rebamipide has antinociceptive
effects and reduces oxidative stress in subchondral bone suggestFig. 7. Therapeutic efﬁcacy of rebamipide in an established OAmodel. Rats were injected
7 days after MIA injection. Behavioral tests (PWL and PWT) showed that signiﬁcant degree o
antinociceptive property in vivo (A and B). Articular cartilages isolated from the rebamipide-t
thinning in a dose-dependent manner, compared with vehicle-treated OA joints (C). iNOS a
OA rats but was reduced in rebamipide-treated OA animals in a dose-dependent manner (C).
are expressed as mean  S.E.M. (error bar) for six animals per group at each time point.the potential of rebamipide in treating OA pain. One recent study
demonstrated the antinociceptive effect of diclofenac that is one of
the nonsteroidal anti-inﬂammatory drugs commonly used for pain
control in OA52. The treatment of diclofenac alleviated pain severity
only on day 7 after partial medial menisectomy but not on day 42.
In contrast with their results, we showed the delayed effect of
rebamipide, up to 3 weeks.with 3 mg of MIA in the right knee. Rebamipide was administered orally every day from
f pain was developed on day 7 and rebamipide at a dose of 3 or 10 mg/kg provided an
reated OA rats (on day 21) showed decreased proteoglycan loss and attenuated cartilage
nd nitrotyrosine expression in chondrocytes was increased in cartilage of MIA-injected
PWL and PWT were conducted right before the administration of rebamipide. The data
Fig. 8. Recovery of anabolic and catabolic activities in human OA chondrocytes following treatment with rebamipide. Human articular chondrocytes from OA patients were
cultured with or without IL-1b in the absence or presence of rebamipide for 48 h following 24 h of starvation. The mRNA expression of catabolic (MMP-1, -3, and -13, and ADAMTS5)
(A) and anticatabolic (TIMP-1 and -3) factors (B) was measured by quantitative real-time PCR. b-Actin was used as the internal control. In human OA chondrocytes, treatment with
rebamipide signiﬁcantly inhibited the expression of IL-1b-induced MMP-1, -3, and -13, and ADAMTS5, but upregulated the expression of TIMP-1 and -3. The data are expressed as
dot plots with mean (bar) for three independent experiments per group. þP < 0.05, þþP < 0.01, and þþþP < 0.001 compared with IL-1b-stimulated chondrocytes; *P < 0.01 and
**P < 0.001 compared with untreated chondrocytes.
S.-J. Moon et al. / Osteoarthritis and Cartilage 20 (2012) 1426e14381436In conclusion, rebamipide treatment attenuated the severity of
articular cartilage destruction in an MIA-induced OA model via
reducing oxidative stress and shifting the ECM homeostasis toward
anabolic activity both in vivo and in vitro. Further study is needed to
understand better how the decrease in oxidative stress caused by
rebamipide treatment induces chondroprotection and changes
cartilage ECM homeostasis, and whether rebamipide affects the
survival of OA chondrocytes. Such investigations may identifywhether the development of OA can be prevented or retarded by
reducing the aging-related induction of oxidative stress.
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